anlotinib,sintilimab
sino biopharmaceuticals,eli lilly,innovent biologics,advenchen
['sintilimab', 'anlotinib', 'nsclc', 'sclc']
dr. baohui han presents sunrise: randomized phase ii study of sintilimab (pd1) and anlotinib (anti-angiogenic tki) in metastatic nsclc. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him